Our Partners

We have established an excellent track record of in-licensing and out-licensing deals with our global and regional partners.

  • Collaboration
  • In-licensing
  • Co-development
  • Out-licensing

Landmark Deals

Global Strategic Partnership with AbbVie

One of the Largest Out-license Deals in Biotech Sector

Total aggregate value under the agreement $1.94B

This deal reinforces I-Mab’s leading position in immuno-oncology and enables us to realize the full potential of our innovation globally.

AbbVie obtains Ex-Greater China rights to develop and commercialize lemzoparlimab; I-Mab retains Greater China rights.

Commercial Partnership with Jumpcan

Among China’s Largest Partnering Deals

Total aggregate value under the agreement $315M + Royalties / Shared Profits*

This deal brings together the strengths of I-Mab’s leadership in innovation and Jumpcan’s leadership in pediatric medicine in China to accelerate the commercialization of eftansomatropin alfa.

* Jumpcan pays US$35 million upfront and US$280 miilion upon development, registration, and sales milestone achievements. Sharing profits on a 50/50 basis, I-Mab is entitled to receive tiered low double-digit royalties on net sales of product.

Partner with Us

We are currently seeking strategic partners in the following areas

  • In-licensing highly differentiated oncology assets
  • Co-development and co-commercialization of our innovative products for the global market

Contact: BD@i-mabbiopharma.com